A Perihilar Variant of Focal Segmental Glomerulosclerosis Due to De novo Branchio-oto-renal Syndrome

Ryosuke Saiki¹, Kan Katayama¹, Masako Kitano², Kayo Tsujimoto¹, Fumika Tanaka¹, Yasuo Suzuki¹, Tomohiro Murata¹, Taira Kurita¹, Ryuji Okamoto¹, Kazuhiko Takeuchi² and Kaoru Dohi¹

Abstract:
Branchio-oto-renal syndrome is an autosomal dominant disorder characterized by branchial anomalies, hearing loss, and renal urinary tract malformations. We herein report a 32-year-old Japanese man with a right preauricular pit, bilateral mixed hearing loss, and malposition of the right kidney who presented with proteinuria. The findings of a left kidney biopsy were compatible with a perihilar variant of secondary focal segmental glomerular sclerosis. A trio exome analysis conducted among the patient and his parents failed to identify the causal gene variant, despite a sporadic pattern. His kidney function remained stable for 11 years with an angiotensin II receptor blocker.

Key words: branchio-oto-renal, de novo, obesity-related nephropathy, proteinuria, trio analysis

(Intern Med 61: 2033-2038, 2022)
(DOI: 10.2169/internalmedicine.8508-21)

Introduction

Branchio-oto-renal (BOR) syndrome is a syndrome characterized by three main symptoms of branchial anomalies, hearing loss, and renal urinary tract malformations. It is considered an autosomal dominant disorder, and its estimated prevalence is 1:40,000 (1). BOR syndrome reportedly has variable expressivity and incomplete penetrance between and within families (2). Renal abnormalities were found to be present in approximately 67% of affected individuals (3). Long-term follow-up of a family with BOR syndrome showed that 40% (4 of 10) of the affected members developed end-stage kidney failure (4).

The gene mutation most commonly encountered in BOR syndrome patients is EYA1, while less frequently SIX1, SIX5, or SALL1 (5, 6). However, mutations in these genes are not always identified in BOR syndrome. Krug et al. reported an identification rate of only 36% (5), and Unzaki et al. reported a rate of 75% (6).

We herein report a case of de novo BOR syndrome in which a genetic analysis was performed to search for mutations.

Case Report

A 32-year-old Japanese man was referred for an evaluation of malposition of the right kidney and proteinuria. He had been born one month prematurely and been complicated with intraventricular hemorrhaging in the newborn period. He had had no repetitive respiratory infections or feeding problems of neonates and infants. He had never been found to have any particular abnormalities during school physical examinations. There was no family history of auditory disturbance, kidney disease, or anomalies in appearance.

His height was 158 cm, and his body weight was 86.8 kg, with a body mass index of 34.8. His blood pressure was 113/80 mmHg, and his pulse rate was 65/min. He did not have intellectual disability, motor development delay, digit anomalies, or specific facial features such as coloboma of the eyes, large nose, or Kabuki-like appearance. Although he did not report any auditory disturbance, an audiometric test...
revealed bilateral mixed hearing loss (Fig. 1a). A physical examination showed a right preauricular pit (Fig. 1b). The laboratory data are shown in Table 1.

Magnetic resonance imaging (MRI) revealed that the right kidney was hypoplastic and positioned abnormally, while the left kidney was normal (Fig. 1c). 99mTc-MAG3 scintigraphy showed a decline in the right kidney function (Fig. 1d). A left kidney biopsy revealed no global sclerosis in 11 glomeruli. The diameter of the glomerulus was large at 295.4 μm. Focal mesangial cell proliferation and hyaline arteriolar sclerosis were observed on Periodic acid-Schiff staining (Fig. 2a). Immunofluorescence showed the focal weak granular deposition of IgA and IgM. An electron microscopic study showed focal effacement of the podocyte foot processes (Fig. 2b). These findings indicated a perihilar variant of secondary focal segmental glomerular sclerosis caused by...
Table 1. Laboratory Data.

| Urinary examination | Blood chemistry |
|---------------------|-----------------|
| pH (4.5-7.5)        | HbA1c (%, 4.7-6.6) | 6.7 |
| Protein (g/g·Cr)    | Glu (mg/dL, 70-110) | 89 |
| Occult blood (+/-)  | TP (g/dL, 6.5-8.0) | 6.9 |
| Glu (-)             | Alb (g/dL, 3.5-5.0) | 4.1 |
| β2MG (μg/L, 5-253)  | BUN (mg/dL, 8-20) | 11 |
| NAG (U/L, 1.0-4.2)  | Cr (mg/dL, 0.60-1.40) | 1 |
|                     | eGFR Cr (mL/min/1.73 m²) | 83.33 |

Complete blood count

|            |             |
|------------|-------------|
| WBC (/μL, 4,300-6,900) | 10,250 |
| RBC (x10^12/L, 446-515) | 557 |
| Hb (g/dL, 14.0-16.0) | 16.3 |
| Ht (%, 43.2-48.6) | 47.1 |
| MCV (fl, 91.3-99.3) | 84.6 |
| Plt (x10^4/μL, 18.0-36.5) | 26.6 |

Serology

|            |             |
|------------|-------------|
| ANA 1:40   | ALP (U/L, 100-350) | 273 |
| MPO-ANCA (U/mL, 0-8.9) | <1.3 |
| PR3-ANCA (U/mL, 0-3.4) | <1.3 |
| Anti-GBM (EU, 0-9) | <10 |
| RF (U/mL, 0-20) | 3 |
| ASLO (U/mL, 0-200) | 132 |
| IgG (mg/dL, 800-1,800) | 1,280 |
| IgA (mg/dL, 80-400) | 180 |
| IgM (mg/dL, 40-194) | 158 |

Alb: albumin, ALP: alkaline phosphatase, ALT: alanine transaminase, ANA: antinuclear antibody, anti-GBM: anti-glomerular basement membrane antibody, ASLO: anti-streptolysin O, AST: aspartate transaminase, β2MG: β2-microglobulin, BUN: blood urea nitrogen, C3: complement 3, C4: complement 4, Ca: calcium, CH50: 50% hemolytic complement activity, Cl: chloride, Cr: creatinine, CRP: C-reactive protein, eGFR: estimated glomerular filtration rate, Glu: glucose, γ-GTP: γ-glutamyltranspeptidase, Hb: hemoglobin, HbA1c: hemoglobin A1c, HDL-C: high-density lipoprotein cholesterol, Ht: hematocrit, IgA: immunoglobulin A, IgG: immunoglobulin G, IgM: immunoglobulin M, IP: inorganic phosphate, K: kalium, LDH: lactate dehydrogenase, MCV: mean corpuscular volume, MPO-ANCA: myeloperoxidase anti-neutrophil cytoplasmic antibody, Na: natrium, NAG: N-acetyl-β-D-glucosaminidase, Plt: platelets, PR3-ANCA: proteinase 3-antineutrophil cytoplasmic antibody, RBC: red blood cells, RF: rheumatoid factor, TC: total cholesterol, TG: triglyceride, TP: total protein, UA: uric acid, WBC: white blood cells

by obesity and unilateral kidney hypoplasia. He started taking angiotensin II receptor blocker after the kidney biopsy. His blood pressure has been stable since then. His estimated glomerular filtration rate and proteinuria remained stable for 11 years (Fig. 3).

While BOR syndrome is suspected of being an autosomal dominant disorder, there was no sign of BOR syndrome in his parents. Therefore, a trio exome analysis was performed among the patient and his parents to search for the de novo mutation that caused BOR syndrome in the patient. There were no pathogenic mutations or copy number variants in EYA1, SIX1, SIX5, or SALL1 in the patient. There were 114 de novo mutations in the patient, of which 31 were exonic or at the splice site. Subsequent Sanger sequencing identified 5 synonymous mutations, and no mutations were confirmed in 14 genes. Common, low, and rare variants were denoted by a minor allele frequency of >5%, 1-5%, and <1%, respectively. Pathogenicity was examined in the ClinVar database if the variant category was low or rare. None of the 12 genes were thought to be pathogenic (Table 2).

There were two nonsense homozygous genes (ORIBI and KRT37), neither of which were thought to be pathogenic (Table 2). While there were 17 newly homozygous or compound heterozygous genes, no mutations were confirmed in 4 genes by subsequent Sanger sequencing. Of the 13 genes, 9 were common variants, 3 were low variants, and 1 was a rare variant (Table 2). FASN p.Ile1113Val was “Likely benign” in the ClinVar database. KRT86 p.Arg241Trp and ZKSCAN2 p.Asp335Glu were “Probably damaging”, while ZKSCAN2 p.Ala454Ser was “Benign” in PolyPhen-2 prediction. KRT86 p.Arg241Trp was “Deleterious” while ZKSCAN2 p.Asp335Glu was “Neutral” in PROVEAN prediction. KRT86 p.Arg241Trp was “Tolerated” in SIFT prediction.

Finally, to detect any copy number variants in EYA1,
Figure 2. (a) A light microscopic study. The diameter of the glomerulus was large at 295.4 μm. There was no inflammatory cell infiltration in the glomeruli on HE staining. PAS staining showed focal mesangial cell proliferation and hyaline arteriolosclerosis. There were no spikes or a bubbling appearance of the glomerular basement membranes on PAM staining. There were no immune complex deposits in the glomeruli on MT staining. Bars =50 μm. HE: Hematoxylin and Eosin staining, PAS: Periodic acid-Schiff stain, PAM: Periodic acid-silver-methenamine stain, MT: Masson-trichrome stain. (b) Electron microscopic study. The podocyte foot processes were focally effaced. The right panel is an enlarged picture of the square in the left panel. Bars =2 μm.

Figure 3. The clinical course. eGFR: estimated glomerular filtration rate
Table 2. Results of a Trio Exome Analysis.

| Gene  | Exome and Sanger sequencing results | Amino acid change | dbSNP  | gnomAD  | 8.3KJPN | Variant category/Pathogenicity |
|-------|------------------------------------|-------------------|--------|---------|---------|-------------------------------|
| LCE5A | c.119G>A, homo                     | p.Cys40Tyr        | rs2105117 | 0.550284 | 0.7341 | Common                        |
| SPTA3 | c.96_122delCCCTGAATCCACCAACACGAGCTTAG, homo | p.Gln48_Gln56del | rs750357968 | 0.5165 | NA | Common                        |
| SACM1L | c.1301A>T, homo                   | p.Tyr434Phe       | rs1465842 | 0.361435 | 0.2701 | Common                        |
| PRPF4B | c.247A>G, homo                     | p.Ile83Val        | rs9503893 | 0.298609 | 0.8027 | Common                        |
| IGFBP3 | c.95C>G, homo                      | p.Ala32Gly        | rs2854746 | 0.61758  | 0.23521 | Common                        |
| ITIH5 | c.1708A>C, hetero                 | p.Thr570Pro       | rs2275069 | 0.495043 | 0.7544 | Common                        |
| DUOXA2 | c.298C>G, homo                     | p.Arg100Gly       | rs2576090 | 0.863151 | 1 | Common                        |
| KCN112 | c.1113C>T, hetero                 | p.Ser371Arg       | rs1612176 | 0.000007 | 0.4999 | Common                        |
| KRTAP9-3 | c.58C>A, homo                     | p.Gln20Lys        | rs112082369 | 0.172332 | 0.28819 | Common                        |
| TCF3  | c.1475C>T, hetero                 | p.Ala492Val       | rs2074882 | 0.028454 | 0.3861 | Common                        |
| FGFI21 | c.521T>C, homo                     | p.Leu174Pro       | rs733920  | 0.739314 | 0.9999 | Common                        |
| SIRPB1 | c.1087G>C, homo                    | p.Ala363Pro       | rs2243603 | 0.194994 | 0.25012 | Common                        |
| OR1B1 | c.574C>T, homo                     | p.Arg192Ter       | rs1476860 | 0.247893 | 0.5983 | Common                        |
| KRT37 | c.703C>T, homo                     | p.Gln235Ter       | rs78158550 | NA | 0.2939 | Common                        |
| HOXD9 | c.806_807insGCA, homo              | p.Gln269dup       | rs56007470 | NA | 0.40459 | Common                        |
| KIF1A | c.2721_2723delGGA, homo            | p.Glu917del       | rs10594016 | 0.5266 | NA | Common                        |
| DSP   | c.1481A>T, homo                    | p.Tyr494Phe       | rs28763961 | 0.006181 | 0.0968 | Common                        |
| FERD3L | c.234_235insGGA, homo              | p.Glu81dup        | rs34966098 | 0.2532 | 0.1946 | Common                        |
| PTPRZ1 | c.4290_4292delTGA, homo            | p.Asp1431del      | rs35947407 | 0.4706 | 0.0004 | Common                        |
| ADAMTS12 | c.1090G>A, homo                   | p.Val364Ile       | rs35767802 | 0.247623 | NA | Common                        |
| KAT76B | c.3310_3312delGGA, homo            | p.Glu1104del      | rs71929101 | 0.3275 | NA | Common                        |
| DUSP16 | c.1090_1098delCCCAGCGGTG, homo     | p.Pro364, Val366del | rs59897494 | 0.2653 | 0.1414 | Common                        |
| KRT86 | c.721C>T, homo                     | p.Arg214Trp       | rs111429470 | 0.000685 | 0.0209 | Low/VUS                       |
| ZKSCAN2 | c.1360G>T, homo                   | p.Ala454Ser      | rs201935635 | 0.000014 | 0.0092 | Rare/VUS                      |
| ZKSCAN2 | c.1005T>A, homo                   | p.Asp355Glu       | rs141526402 | 0.00177 | 0.0156 | Low/VUS                       |
| TNK1  | c.832G>A, homo                     | p.Val278Ile       | rs55939858 | 0.004163 | 0.0748 | Common                        |
| FASN  | c.3337A>G, homo                    | p.Ile1113Val     | rs201182683 | 0.00057 | 0.0115 | Low/Likely benign             |

Del: deletion, dup: duplication, hetero: heterozygous, homo: homozygous, ins: insertion, NA: not available, VUS: variant of uncertain significance

which was the most strongly suspected causative gene, quantitative polymerase chain reaction (qPCR) of each exon in EYA1 normalized with ACTB or GAPDH was performed, providing negative results. Overall, the trio exome analysis failed to identify the causative mutation in the patient. We therefore focused on searching for a non-allelic homologous recombination around the EYA1 gene. Long polymerase chain reaction failed to detect any proximal or distal breakpoints.

Discussion

We experienced a case of de novo BOR syndrome. Chang et al. proposed clinical criteria for BOR syndrome, which included four major criteria of branchial anomalies, deafness, preauricular pits, and renal anomalies, as well as five minor criteria of external ear anomalies, middle ear anomalies, inner ear anomalies, preauricular tags, and others (2). The present patient met three of the major criteria (deafness, preauricular pits, and renal anomalies), so he was diagnosed with BOR syndrome.

While BOR syndrome is suspected of being an autosomal dominant disorder, the present case seemed to be sporadic, prompting us to perform a genetic analysis among the patient and his parents. However, a trio exome analysis provided negative results. Furthermore, long polymerase chain reaction was performed to search for non-allelic homologous recombination (7), which also provided negative results. These results were considered consistent with those of previous reports, wherein the identification rates of the causative gene in BOR syndrome were 36% and 75% (5, 6). One limitation of the present study was that we did not investigate deep intronic variants. Furthermore, we did not perform a multiplex ligation-dependent probe amplification analysis in EYA1, performing qPCR instead. An event at the time of birth might affect the gene expression related to BOR syn-
drome, as our patient was born one month early.

Although the patient had proteinuria with a reduced right kidney function at the first visit, his kidney function did not decline for 11 years. The clinical condition of the present case was thought to be similar to that of patients with unilateral kidney hypoplasia, as $^{99m}$Tc-MAG3 scintigraphy showed an almost normal function in the left kidney. A previous report demonstrated that uninephrectomy in army personnel who lost a kidney due to trauma led to few major adverse consequences over 45 years (8). Furthermore, another study showed that the long-term kidney function of donors was stable over 40 years (9).

The results of a left kidney biopsy showed enlarged glomeruli with focal foot process effacement, suggesting compensatory glomerular hyperfiltration. A previous report showed segmental hyalinosis and mesangial proliferation of varying degrees (10). Another report showed a patient with BOR syndrome who had focal glomerulosclerosis (11). In the present case, angiotensin II receptor blocker was initiated to reduce the increased intraglomerular pressure. A reduction in body weight is needed in the present case, since an increased intraglomerular pressure due to obesity has been reported to raise the risk of developing chronic kidney disease (12).

In conclusion, we experienced a case of de novo BOR syndrome. The long-term kidney function was stable with conservative therapy despite unilateral kidney hypoplasia.

Consent to participate was obtained for genetic screening of the patient. The genetic analyses were approved by the Institutional Review Board of Mie University Graduate School of Medicine (reference number H2019-113).

Written informed consent was obtained from the patient for the publication of this case report.

The authors state that they have no Conflict of Interest (COI).

References

1. Fraser FC, Sproule JR, Halal F. Frequency of the branchio-oto-renal (BOR) syndrome in children with profound hearing loss. Am J Med Genet 7: 341-349, 1980.
2. Chang EH, Menezes M, Meyer NC, et al. Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat 23: 582-589, 2004.
3. Chen A, Francis M, Li N, Cremers CW, et al. Phenotypic manifestations of branchio-oto-renal syndrome. Am J Med Genet 58: 365-370, 1995.
4. Pierides AM, Athanasiou Y, Demetriou K, Koptides M, Deltas CC. A family with the branchio-oto-renal syndrome: clinical and genetic correlations. Nephrol Dial Transplant 17: 1014-1018, 2002.
5. Krug P, Morinière V, Marlin S, et al. Mutation screening of the EYA1, SIX1, and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations. Hum Mutat 32: 183-190, 2011.
6. Unzaki A, Morisada N, Nozu K, et al. Clinically diverse phenotypes and genotypes of patients with branchio-oto-renal syndrome. J Hum Genet 63: 647-656, 2018.
7. Brophy PD, Alasti F, Darbro BW, et al. Genome-wide copy number variation analysis of a Branchio-oto-renal syndrome cohort identifies a recombination hotspot and implicates new candidate genes. Hum Genet 132: 1339-1350, 2013.
8. Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW. Forty-five year follow-up after uninephrectomy. Kidney Int 43: 1110-1115, 1993.
9. Fehrman-Ekholm I, Kvarnström N, Söfteland JM, et al. Post-nephrectomy development of renal function in living kidney donors: a cross-sectional retrospective study. Nephrol Dial Transplant 26: 2377-2381, 2011.
10. Dumas R, Uziel A, Baland P, Segond A. Glomerular lesions in the branchio-oto-renal (BOR) syndrome. Int J Pediatr Nephrol 3: 67-70, 1982.
11. Gigante M, d’Altilia M, Montemurno E, et al. Branchio-Oto-Renal Syndrome (BOR) associated with focal glomerulosclerosis in a patient with a novel EYA1 splice site mutation. BMC Nephrol 14: 60, 2013.
12. Kovesdy CP, L. Furth S, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Clin Kidney J 10: 1-8, 2017.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).